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surfactant protein B inversely related to
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Background: Alveolar–capillary membrane leaks can increase the amount of surfactant protein B (SP-B) in the
bloodstream. The purpose of this study was to measure the concentration of C-proSP-B, a SP-B precursor that
includes C-terminal domains, in various body fluids of newborn infants and determine its dependence on
gestational age.
Methods: C-pro-SPB was measured in amniotic fluid and umbilical cord blood at birth, and in peripheral blood
and urine on postnatal day 3 in 137 newborn infants with a median birth weight of 2015 g (range, 550–4475 g)
and gestational age of 34 weeks (range, 23–42 weeks).
Results: C-proSP-B levels differed more than 100-fold among samples. The levels (median; interquartile range) were
highest in peripheral blood (655.6 ng/mL; 419.0-1467.0 ng/mL) and lowest in urine (3.08 ng/mL; 2.96-3.35 ng/mL).
C-proSP-B levels in amniotic fluid (314.9 ng/mL; 192.7–603.6 ng/mL) were approximately half of those in peripheral
blood. In cord blood C-proSP-B was slightly lower (589.1 ng/mL; 181.2-1129.0 ng/mL) compared with peripheral
blood. C-proSP-B levels significantly increased in all the fluids sampled except urine with decreasing gestational age
(p < 0.001).
Conclusions: This novel assay allows for the quantitative measurement of C-proSP-B in blood and amniotic fluid.
The dependence of C-proSP-B on gestational age may hamper its use for the detection of alveolar leaks in preterm
newborns.
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Pulmonary surfactant is synthesized by type II pneu-
mocytes and secreted into the airways of the lung
beginning at 24 weeks gestation. Its deficiency or
dysfunction is the hallmark of respiratory distress
syndrome in preterm infants [1,2]. Pulmonary surfactant
consists of a complex of lipids and specific proteins,
including surfactant proteins (SP) A, B, C and D. Of
these surfactant proteins, SP-B is the only one that is
absolutely essential for initiating breathing and life
[3-5]. The highly hydrophobic SP-B enhances the
absorption of phospholipids onto the air–water interface* Correspondence: christoph.czernik@charite.de
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reproduction in any medium, provided the orand optimizes surface tension reduction [6,7]. SP-B is a
relatively small (79 amino acids) hydrophobic polypeptide
that is synthesized as a longer, 381-amino-acid precursor
that undergoes a complex maturation process along the
exocytic pathway of type II pneumocytes [8]. Processing
of the SP-B precursor includes proteolytic cleavage of
N- and C-terminal domains in at least three different steps.
Cleavage of the N-terminal (24–200) and C-terminal
(280–381) flanking domains generates the biophysically
active, mature SP-B. C-ProSP-B is a transient intermediate
in the synthesis of SP-B that does not accumulate in type
II pneumocytes [3].
Although surfactant proteins are normally only found
in appreciable amounts in the lung, leakage of SP-A,
SP-B and SP-D into the circulation has been reported
in a number of respiratory disorders [9-14] and cardiacLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the circulation is unknown; there is, however, strong
evidence that a bidirectional plasma protein flux occurs
in the lungs, the magnitude of which depends on
disease severity [19,20]. Jobe et al. [21] showed that
this bidirectional flux from the alveoli increased as
gestational age decreased in prematurely delivered,
ventilated lambs.
Currently, there are only a few reports describing the
measurement of SP-A levels in cord blood and sera from
neonates within 24 hours after birth [22,23]. To date,
there are no data regarding C-proSP-B concentrations
in the blood of newborn infants. We hypothesized that
C-proSP-B could be measured in different samples from
newborn infants and that these levels would be correlated
with lung maturation. The aim of this exploratory study
was to measure C-proSP-B in cord and peripheral blood,
amniotic fluid, and urine of preterm and term newborn
infants with gestational ages between 24 and 42 weeks.
Methods
Patients and protocol
Newborn infants delivered at the Charité University
Hospital between October 2009 and May 2011 were
enrolled in the study. Infants who died in the first days
of life were excluded. The study protocol was approved
by the local institutional review board (Ethikkommission
der Charité, #EA2/083/09). Written informed consent for
sampling was obtained for infants of imminent premature
birth before delivery, or on the first day of life in some
cases.
Measurement of C-proSP-B in different samples
Samples of amniotic fluid (5 ml) were collected during
labor prior to delivery and umbilical cord blood (1 ml)
was obtained at birth. Peripheral blood samples were
taken within 36 to 72 hours of age through umbilical
artery catheter aspiration or venous puncture as part of
routine sampling. Urine was collected in plastic bags at
the same time. The samples were centrifuged at 7000 rpm
(Eppendorf microcentrifuge) for 3 minutes. Cell-free
plasma, urine and amniotic fluid were stored at −20°C
until C-pro-SPB analysis. The samples were batched
and run together after collection was complete. The
tests were performed in a single run and in a blinded
manner using a new C-proSP-B electrochemiluminescence
immunoassay kit employing a Tris(bipyridyl)-ruthenium
(II) complex as a label (Roche Diagnostics, Mannheim
Germany), as described by the manufacturer. Briefly,
biotinylated capture antibody, ruthenium-labeled detection
antibody, and sample or standard material (10 μl) were
first incubated in a homogeneous phase for 9 minutes
at 37°C. Then, streptavidin-coated beads were added
and incubated for 9 minutes to allow binding of theformed immune complexes to the microparticles. After the
second incubation, the reaction mixture was transferred
to the measuring cell, where beads were captured on
the electrode surface by a magnet. The measuring cell
was washed to remove unbound label and filled with
detection buffer containing Tris-propylamine. After
applying voltage to the electrode, the emitted chemilumin-
escence was detected by a photomultiplier. Results were
determined using a two-point calibration curve. C-proSP-
B values are given as nanograms per milliliter, and were
measurable within a range of 0.1 to 3000 ng/mL.
Statistical analysis
Patient characteristics were described by median and
range and compared using the Mann–Whitney rank test.
Measured C-ProSP-B values were described by median and
interquartile range (IQR) and compared by using Wilcoxon
test for paired samples or the Mann–Whitney rank test
for independent samples, as appropriate. Spearman rank
correlation coefficients (rS) were calculated to investi-
gate the relationship of the C-ProSP-B concentrations
between paired samples. A non-linear regression analysis
was performed by linearization of nonlinear models to
investigate the relationship between C-ProSP-B and
gestational age using the Pearson correlation coefficient
as a measure of the goodness of fit. Statistical analyses
were performed using Statgraphics Centurion® software
(Version 16.0, Statpoint Inc., Herndon, Virginia, USA)
and MEDCALC (Version 12.2.1.0; MedCalc Software,




C-proSP-B was measured in 137 patients with a median
birth weight of 2240 g (range, 550–4475 g) and a gesta-
tional age of 34 weeks (range, 23–42 weeks). 80 (58%)
infants were born before 37 gestational weeks (preterm
infants) and 17 (12%) infants with a mean gestational
age of 28 (24–32) weeks received antenatal steroids.
Postnatal mechanical ventilation was necessary for 8
(6%) infants.
A total of 265 C-proSP-B measurements were per-
formed on four different samples; however, not all samples
could be obtained from every patient. As shown in Table 1,
the largest numbers of measurements were obtained from
amniotic fluid (N = 79) and urine (N = 77), whereas the
number of blood measurements was lower (peripheral
blood, N = 63; cord blood, N = 46).
Comparisons of different samples
To investigate differences in C-proSP-B levels among
the four different samples, we evaluated paired mea-
surements from the same patient (Figure 1). The highest
Table 1 C-proSP-B in different samples at which the
highest levels were found in the peripheral blood
(presented as median and IQR)
Sample N C-proSP-B (ng/mL)
Peripheral blood 63 655.6 (419.0–1467.0)
Cord blood 46 589.1 (181.2–1129.0)
Amniotic fluid 79 314.9 (192.7–603.6)
Urine 77 3.08 (2.96–3.35)
N = number of samples.
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was used as a reference (defined as 100%); the levels
in all other samples were significantly lower. There
was a strong correlation between C-proSP-B levels in
peripheral and cord blood (N = 18 paired samples, rS =
0.759, p < 0.001). Although C-proSP-B levels in cord
blood trended about one-third lower than those in
peripheral blood, this difference fell just short of statistical
significance (p = 0.053) due to high intersubject variability,
which ranged from near 0% to 200% relative to peripheral
blood. C-proSP-B levels measured in amniotic fluid
were also significantly correlated with C-proSP-B levels
measured in peripheral blood (N = 25 paired samples,
rS = 0.709, p < 0.001), although they were appro-
ximately half those of peripheral blood. The lowest
C-ProSP-B concentrations were seen in urine, where
levels were only 0.3% of those in peripheral blood;
there was only a weak correlation between C-proSP-B
levels in these two samples (N = 32 paired samples,


























Figure 1 Paired measurements of the level of C-proSP-B in cord bloo
which was set at 100%. The p-value describes the statistical significance oDependence of C-proSP-B on gestational age
With the exception of urine, all samples showed a sig-
nificant dependence of C-proSP-B levels on gestational
age. For each of the remaining three samples, C-proSP-B
levels increased significantly (p < 0.001) with decreasing
gestational age (Figure 2). In each case, the best cor-
relation was found with the reciprocal value of the
gestational age.
The effect of antenatal steroid treatment and mechanical
ventilation on C-proSP-B could not be analyzed in this
study due to drop outs in the different samples. The
incidence of infants who received antenatal steroid
treatment and mechanical ventilation in the four sample
groups was very small (≤6 and ≤4 infants, respectively).Discussion
The study showed that C-proSP-B can be measured in
samples of the peripheral and cord blood, amniotic fluid
and urine of newborn infants. However, there were
distinct differences among the samples investigated. C-
proSP-B concentrations differed more than 100-fold
among the samples, and were generally highest in the
peripheral blood and lowest in urine. C-proSP-B concentra-
tions in peripheral blood were significantly correlated with
those in samples of cord blood and amniotic fluid, but only
weakly with those in urine samples. Furthermore, with
the exception of urine, C-proSP-B levels increased with
decreasing gestational age. How C-proSP-B patterns change
with further postnatal development is still unknown.
The dependence of C-proSP-B on maturity may hamper
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C-proSP-B = -1498.3 + 82176.8/GA
r = 0.544 (N=63)
Gestational age (weeks)
C-proSP-B = -2535.6 + 110977/GA
r = 0.639 (N=46)
Gestational age (weeks)
C-proSP-B = -1312.1 + 59485.7/GA




















































Correlation of C-proSP-B with gestational age
Figure 2 Increase in C-proSP-B with decreasing gestational age
in peripheral (top) and cord blood (middle) and amniotic fluid
(bottom). Presented are the regression curve, the correlation
coefficient r and the number of samples N.
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ventilator-induced lung injury, as shown in adults [24,25].
Thus, increased levels of C-proSP-B are difficult to inter-
pret. Although non-invasive methods are currently favored
[26,27], intubation and mechanical ventilation are often
unavoidable, and the immature lung tissue of these infants
is at increased risk of damage. In a review, Takahashi et al.
[25] reported that increased levels of surfactant proteins
in body fluids reflect alterations of capillary–alveolar
membranes and lung maturity. Determining surfactant
proteins in body fluids may aid in monitoring the
course of pulmonary diseases, such as pulmonary alveolar
proteinosis, respiratory distress syndrome and pneumonia.
Awasthi et al. [28] showed that in premature newbornbaboons, the amounts of SP-A and SP-D in lavage fluid
were indicators of infection risk in the pathogenesis of
neonatal chronic lung disease.
Moreover, Beresford and Shaw described how lower
bronchoalveolar lavage SP-B and SP-D concentrations in
preterm infants ventilated for respiratory distress syndrome
were associated with worse clinical prognoses [29]. In this
context, Keller et al. [30] demonstrated recently in preterm
infants that late administration of a surfactant containing
SP-B surfactant transiently increases SP-B content in the
lung aspirates, possibly leading to improved short- and
long-term respiratory outcomes. The diagnostic value of
C-proSP-B in newborns in this context is still unknown and
will require additional clinical studies. However investiga-
tion into the diagnostic value of C-proSP-B as a biomarker
should consider that C-proSP-B is highly dependent on
gestational age as shown in the present study.
To the best of our knowledge, this is the first study in
which C-proSP-B was measured quantitatively in different
samples from newborn infants. The four samples investi-
gated are commonly collected for perinatal diagnostics,
though it was not possible to obtain all four from every
patient. Amniotic fluid can only be obtained non-
invasively during delivery. Cord blood is commonly
available, though it is difficult to obtain in some patients
due to constriction of the vessels. Peripheral blood and
urine samples can be collected more reliably, though this
requires puncturing a peripheral vessel or using a urine
bag, respectively.
It was not surprising that the highest levels of C-proSP-B
were found in the peripheral blood. SP-B is a lung-specific
protein, so SP-B in amniotic fluid is believed to come
directly from the alveolar space, whereas SP-B in blood
is thought to have permeated into the circulation from
the alveolar space. In this context, SP-B in amniotic
fluid transported by fetal breathing movements [31,32]
should directly reflect that in the alveolar space, whereas
SP-B in blood is influenced by lung permeability, which
increases in direct relationship to the severity of lung
damage. The lower concentration of C-proSP-B in amniotic
fluid than in peripheral blood may be caused by dilution
processes, because the amniotic fluid volume is much
greater than the infant’s blood volume. The extremely low
concentration measured in urine may reflect impaired
transport from blood to urine. The renal clearance of
proteins is limited by their molecular mass, hydrophobicity
and kidney function, which is related to maturity [33].
This pilot study has several limitations. Firstly, as
discussed above, we could not obtain peripheral and
cord blood, amniotic fluid and urine samples from every
patient, hampering the comparability of pro-protein levels
among different samples. Secondly, ethical considerations
prevented us from performing longitudinal measurements;
accordingly, we could not assess the pattern of postnatal
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of patients treated und the sample drop out rate, we could
not investigate the effect of prenatal steroid treatment
and mechanical ventilation on C-proSP-B. Furthermore,
we have no C-proSP-B measurements from infants after
long-term ventilator support, meaning the effect of lung
injury on C-proSP-B could not be quantified. This would
need to be addressed in future clinical studies.
Conclusions
C-proSP-B can be measured quantitatively in different
samples from newborn infants. The highest concentrations
of C-proSP-B were found in peripheral blood. With the
exception of urine, C-proSP-B levels increased with de-
creasing gestational age, a factor that should be considered
in the interpretation of elevated levels.
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